{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:52:35Z","timestamp":1789199555367,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Science and Technology Project","award":["Z181100001718215"],"award-info":[{"award-number":["Z181100001718215"]}]},{"DOI":"10.13039\/501100009580","name":"PLA general hospital","doi-asserted-by":"crossref","award":["CX19011"],"award-info":[{"award-number":["CX19011"]}],"id":[{"id":"10.13039\/501100009580","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADCs) have been the preferred regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) after trastuzumab. Unfortunately, there is little data showing which ADCs should be chosen for those patients whose treatment with tyrosine kinase inhibitors (TKIs) failed. This study aims to analyze the efficacy and safety between novel anti-HER2 ADCs and trastuzumab emtansine (T-DM1) for those with TKIs failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>HER2-positive MBC using ADCs from January 2013 to June 2022 were included, and all of them were treated with TKIs. The primary study endpoint was progression-free survival (PFS), and the secondary study endpoints were objective response rate (ORR), clinical benefit rate (CBR), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 144 patients with 73 patients in the novel anti-HER2 ADCs group and 71 patients in the T-DM1 group. In these novel ADCs, 30 patients received trastuzumab deruxtecan (T-Dxd), 43 patients receive other novel ADCs. The median PFS in the novel ADCs group and T-DM1 group were 7.0 months versus 4.0 months, respectively, and ORR was 54.8% versus 22.5%, CBR was 65.8% versus 47.9%, respectively. In subgroups analysis, the PFS were both significantly improved in patients receiving T-Dxd and other novel ADCs compared with T-DM1. The most common grades 3-4 adverse events in the novel anti-HER-2 ADCs group were neutropenia (20.5%) and thrombocytopenia (28.1%) in the T-DM1 group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with HER2-positive MBC previously treated with TKIs, both T-Dxd and other novel anti-HER2 ADCs yielded statistically significant better PFS than T-DM1 did, with tolerable toxicities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad127","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T04:40:32Z","timestamp":1684816832000},"page":"e859-e866","source":"Crossref","is-referenced-by-count":14,"title":["Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment"],"prefix":"10.1093","volume":"28","author":[{"given":"Chenchen","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"},{"name":"Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"10200","key":"2023100311184329100_CIT0001","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"2023100311184329100_CIT0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2023100311184329100_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"19","key":"2023100311184329100_CIT0004","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"2023100311184329100_CIT0005","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel \u00adher2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023100311184329100_CIT0006","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100311184329100_CIT0007","year":"2022"},{"key":"2023100311184329100_CIT0008","year":"2021"},{"key":"2023100311184329100_CIT0009","year":"2021"},{"issue":"1","key":"2023100311184329100_CIT0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","author":"Yan","year":"2020","journal-title":"Transl Breast Cancer Res"},{"issue":"27","key":"2023100311184329100_CIT0011","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023100311184329100_CIT0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21037\/atm-20-4054","article-title":"Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study","volume":"9","author":"Li","year":"2020","journal-title":"Ann Transl Med"},{"issue":"3","key":"2023100311184329100_CIT0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/tbcr-22-21","article-title":"Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022","author":"Jiang","year":"2022","journal-title":"Transl Breast Cancer Res"},{"issue":"3","key":"2023100311184329100_CIT0014","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib Ther"},{"issue":"156","key":"2023100311184329100_CIT0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2019.12.037","article-title":"ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor e","volume":"473","author":"Barok","year":"2020","journal-title":"Cancer Lett"},{"key":"2023100311184329100_CIT0016","first-page":"Of1","article-title":"Phase I trial of a novel anti-HER2 \u00adantibody-drug conjugate, ARX788, for the treatment of \u00adHE","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023100311184329100_CIT0017","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"issue":"7","key":"2023100311184329100_CIT0018","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated \u00adHER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023100311184329100_CIT0019","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2023100311184329100_CIT0020","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023100311184329100_CIT0021","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jval.2017.04.003","article-title":"Predicting real-world effectiveness of cancer therapies using overall survival and \u00adprogression-free survival from clinical trials: empirical evidence for the ASCO value framework","volume":"20","author":"Lakdawalla","year":"2017","journal-title":"Value Health"},{"issue":"1048781","key":"2023100311184329100_CIT0022","article-title":"Different treatment regimens in breast cancer visceral crisis: a retrospective cohort study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"2023100311184329100_CIT0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"2023100311184329100_CIT0024","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2023100311184329100_CIT0025","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"12","key":"2023100311184329100_CIT0026","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e859\/51821355\/oyad127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e859\/51821355\/oyad127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:26:30Z","timestamp":1696332390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/10\/e859\/7176004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad127","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,5,22]]}}}